Denali's AVLAYAH sales beat estimates, and management expects $30.0 million to $32.0 million in fourth-quarter sales. Net income included a one-time $194.0 million voucher-sale gain, but the sales beat, wider coverage, and permanent billing code make the report favorable.
More patients may be able to get AVLAYAH, and the permanent billing code may make payment easier. But the reported profit included a one-time voucher sale, so sales progress is a clearer sign of the business than the profit figure.
Follow Denali Therapeutics (DNLI) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for DNLI